Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 22, No 14S (July 15 Supplement), 2004: 538
© 2004 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Tubiana-Hulin, M. Articles by Spyratos, F. Search for Related Content PubMed Articles by Tubiana-Hulin, M. Articles by Spyratos, F.

Abstract

Response to neo-adjuvant exemestane in post-menopausal breast cancer patients: correlation with biological factors measured by real-time quantitative RT-PCR (QRT-PCR)

Huguenin, Saint Cloud, France

538

Background: The effects of aromatase inhibitors on tumor biological factors in the neo-adjuvant setting are still not well documented and predictive factors of response are needed in addition to hormone receptor status. Methods: 41 postmenopausal women with estrogen and/or progesterone receptor (ER, PR) positive operable breast cancer received neoadjuvant exemestane 25 mg once daily, during 16 weeks. Frozen and formalin-fixed tumor tissues were collected before treatment and at surgery for pathological and biological markers measured by immunohistochemistry (IHC) and QRT-PCR. We analyzed ER, PgR, Ki67, HER2 at the protein and mRNA level (IHC and QRT-PCR) and ERß, aromatase and COX-2 (QRT-PCR). Results: QRT-PCR was performed on pre-treatment biopsies in 31 cases. The median quantity of total RNA was 4,5 µg (range: 0.3–22,7). For each target gene, median and range mRNA values relative to the TBP reference gene were : ER : 306 (48–893) ; ERß: 34.6 (3.5–278.5) ; PgR: 263 (2–2738) ; Ki67: 18.5 (3.3–66.5) ; HER2: 532.5 (2–10467); Aromatase: 515.5 (55–3608); COX-2: 5.1 (1–59.2). There was a statistically significant positive correlation between IHC and QRT-PCR measurements of PgR, Ki-67 and HER2 (r=0.81 p<0.0001; r=0.56 p=0.001; r=0.53 p=0.002). Aromatase mRNA expression was positively correlated with COX-2 (0.51 p=0.001) and ERß mRNA (0.39 p=0.02). A clinical response was observed in 31 patients (75.6%) ; a pathological response (Sataloff score>50%) in 6 patients (17.6%). No significant relation was found between any initial biological factor and clinical or histological response. Exemestane treatment was associated with no change in ER expression and a significant reduction in PgR and Ki-67 expression (IHC and QRT-PCR). Conclusions: Quantitative assessment of gene expression at the mRNA level is feasible and reproducible on small biopsies by QRT-PCR. So far, no correlation was found between pre-treatment biological factors and response; post-treatment QRT-PCR measurements will be compared to pre-treatment data and response.

No significant financial relationships to disclose.

Abstract presentation from the 2004 ASCO Annual Meeting